22			SHEET <u>1</u> 0F <u>2</u>
4	Substitute for force 1449A/PTO	ATTORNEY'S NO. 032775-047	APPLICATION No. 209/847,355
	INFORMATION DISCLOSURE	APPLICANT Donald Morris, et al.	GEN Sn?
đ	TESTATEMENT BY APPLICANT	FILING DATE May 3, 2001	GROUP 1636 E
-			2

**U.S. PATENT DOCUMENTS** & TRADE U.S. Patent Document Date of Publication Examiner Kind Code Name of Patentee or Applicant (MM-DD-YYYY) (if known) of Cited Document Initials Number 10-24-00 6,136,307 Lee, et al. FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Publication Translation Kind Code Examiner (MM-DD-YYYY) Number (if known) Country Initials 09-01-94 WO 94/18992 11-10-1994 -X40 WO 94/25627 WO 02-25-1999 WO 99/08692 NON PATENT LITERATURE DOCUMENTS Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Examiner Initials publisher, city and/or country where published. Bar-Eli, N., et al., "preferential cytotoxic effect of Newcastle disease virus on lymphoma cells", J. Cancer Res. Clin. Oncol. 122: 409-415 (1996). Bensinger, W.I., "Should we purge?", Bone Marrow Transplant. 21:113-115 (1998). Bischoff JR. et al., "An Adenovirus Mutant that Replicates Selectively in p53-Deficient Human Tumor", Science-274(5286):373-6-(-1996):--Blagoslelonny, M.V., et al., "in vitro Evaluation of a p53-Expressing Adenovirus as an Anti-Cancer Drug", Int. J. Cancer 67(3):386-392 (1996). Bos, J.L., "Ras Oncogenes in Human Cancer: A Review", Canc. Res. 49(17): 4682-4689 (1989). Chang et al., PNAS 89:4825-4829 (1992). Chang, H.W. et al., Virology 194:537-547 (1993). Chang et al., J. Virol. 69:6605-6608 (1995). Coffey, M.C., et al., "Reovirus Therapy of Tumors with Activated Ras Pathway", Science 282:1332-1334 Duggan, P.R., et al., "Predictive factors for long-term engraftment of autologous blood stem cells", Bone Marrow Transplantation 26(12): 1299-1304 (2000). Fueyo, J., et al., "A Mutant Oncolytic Adenovirus Targeting the Rb Pathway Produces Anti-Glioma Effect in Vivo", Oncogene 19(1):2-12 (2000). Gao, J., B. Tombal and J.T. Isaacs, "Rapid in situ hybridization technique for detecting malignant mouse cell contamination in human xenograft tissue from nude mice and in vitro cultures from such xenografts", Prostate **39(1)**: 67-70 (1999) Haig, D.M., et al., *Immunology* 93(3):335-340 (1998). He, B., et al., *Proc. Nat. Acad. Sci.* 94: 843-848 (1997). Kawagishi-Kobayashi, M., et al., Mol. Cell. Biology 17:4146-4158 (1997). Nemunaitis, J., Invest. New Drugs 17:375-386 (1999). Nielsen LL., et al., "P53 Tumor Suppressor Gene Therapy for Cancer", Cancer Gene Ther. 5(1):52-63

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Substitute for form 1449A/PTO

P ENFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTORNEY'S II 032775-047

APPLICATION No. 09/847,355

APPLICANT

Donald Morris, et al.

FILING DATE May 3, 2001 GROUP

MT 3 1 500				
l	Neto, Y. et al., "Autologous stem-cell transplantation for solid tumors in adults", Hematol. Oncol. Clin. Sorth Am. 13(5):939-968 (1999).			
BE	Norman, K., et al., "Reovirus as a novel oncolytic agent", J. Clin. Invest. 105 (8): 1035-1038 (2000).			
DL	Reichard, K.W., et al., "Newcastle Disease Virus Selectively Kills Human Tumor Cells", J. of Surgical Research 52:448-453 (1992).			
DL	Stojdl, D.F., et al., "Exploiting Tumor-Specific Defects in the Interferon Pathway with a Previously Unknown Oncolytic Virus", Nat. Med. 6(7):821-825 (2000).			
DC	Romano et al., Mol. and Cell. Bio. 18:7304-7316 (1998).			
01	Sharp et al., Virol. 250:302-315 (1998).			
DL	Spyridonidis, A. et al., "Minimal residual disease in autologous hematopoietic harvests from breast cancer patients", Annals of Onc. 9:821-826 (1998).			
DL	Steele, T.A., "Recent Developments in the Virus Therapy of Cancer", <i>Proc. Soc. Exp. Biol. Med.</i> . 223:118-127 (2000).			
DL.	Stewart, D.A., et al., "Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens", <i>Bone Marrow Transplant.</i> 23(2): 111-117 (1999).			
DL.	Strong, J.E., et al., "The Molecular Basis of Viral Oncolysis: Usurpation of the Ras Signaling Pathway by Reovirus", <i>EMBO J.</i> 17:3351-3362 (1998).			
DL	Strong, J.E., et al., "Evidence that the Epidermal Growth Factor Receptor on Host Cells Confers Reovirus Infection Efficiency", <i>Virology</i> <b>197</b> (1):405-411 (1993).			
DL	Strong, J.E., et al., "The v-erbV oncogene confers enhanced cellular susceptibility to reovirus infection", 7. Virol. 70:612-616 (1996).			
DC	Wiman KG, "New p53-Based Anti-Cancer Therapeutic Strategies", Med Oncol. 15(4):222-8 (1998).			
Winter, J.N., "High-dose therapy with stem-cell transplantation in the malignant lymphomas", O. (Huntingt) 13(12):1635-1645 (1999).				
DC	Yoon, S.S., et al., "An Oncolytic Herpes Simplex Virus Type I Selectively Destroys Diffuse Liver Metastases from Colon Carcinoma", FASEB J 14:301-311(2000).			
D	Zorn, U. et al., "Induction of Cytokines and Cytotoxicity against Tumor Cells by Newcastle Disease Virus", Cancer Biotherapy 9(3):22-235 (1994).			
Examiner	David Combiettson Date Considered 8/15/02			